Oliver Sartor is, since 2010, the C.E. and Bernadine Laborde Professor of Cancer Research, and Medical Director, at the Tulane Cancer Center, in New Orleans, LA, USA, and serves as the Assistant Dean for Oncology at Tulane University School of Medicine, in New Orleans. Prof. Sartor graduated from Tulane Medical School in 1982, and was elected President of the AOA Honour Medical Society. After completing a residency in internal medicine at Tulane University in 1986, he completed a fellowship in the medical oncology branch of the National Cancer Institute in Bethesda, MD, USA. Following a number of years as a faculty member at Louisiana State University Medical School, in New Orleans, and Harvard Medical School, in Cambridge, MA, USA, Prof. Sartor returned to Tulane Medical School, in 2008, to accept a joint appointment in the Departments of Medicine and Urology.
Over the years, Prof. Sartor’s clinical and research interests have focused broadly on prostate cancer. He is involved in a wide variety of clinical trials covering both translational issues and advanced treatments. Prof. Sartor has served as Principal Investigator or Co-Principal Investigator for 3 trials that were pivotal for US Food and Drug Administration (FDA) approval (samarium-153 EDTMP, cabazitaxel, and radium-223).
Prof. Sartor is Medical Oncology Chair of the Genitourinary Cancer Committee for the NRG Oncology Foundation, a national clinical trials cooperative, and serves as a member of the board of the Louisiana Cancer Research Consortium, a multi-institution collaborative cancer research effort. From 2014 to 2019, he served on the National Cancer Institute’s Board of Scientific Counsellors for Clinical Sciences and Epidemiology. Prof. Sartor is also a grant reviewer for both the Prostate Cancer Foundation and the Movember Foundation.
Prof. Sartor’s scientific publications – more than 400 since 1980 – range from genetic studies on prostate cancer and studies of ethnic populations, to clinical trials involving novel agents. To date, he has given hundreds of invited lectures and presentations on advanced prostate cancer at meetings across 33 countries.
EM-40027 - Date of preparation: August 2020